OncoCyte News

Needham: Reiterated OncoCyte (OCX.US) rating, adjusted from buy to buy rating, target price $4.25.

Zhitong FinanceMay 16 06:31

OncoCyte Analyst Ratings

BenzingaMay 16 06:27

Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

BenzingaMay 16 06:28

OncoCyte's Strategic Initiatives and Financial Health Garner Buy Rating

TipRanksMay 16 05:19

Needham: Maintaining the OncoCyte (OCX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $3.60 to $4.25.

Zhitong FinanceApr 24 13:40

OncoCyte Analyst Ratings

BenzingaApr 24 13:38

Strong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiency

TipRanksApr 24 09:45

Stephens & Co. : The OncoCyte (OCX.US) rating was reaffirmed and adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, with a target price of $4.00.

Zhitong FinanceApr 17 09:20

OncoCyte Analyst Ratings

BenzingaApr 17 09:13

Benchmark: OncoCyte (OCX.US) rating was confirmed and adjusted from Speculative Buy to Specified Buy, with a target price of $5.00.

Zhitong FinanceApr 15 10:11

OncoCyte Analyst Ratings

BenzingaApr 15 10:06

Benchmark Reiterates Speculative Buy on OncoCyte, Maintains $5 Price Target

BenzingaApr 15 10:09

BTIG Reaffirms Their Hold Rating on OncoCyte (OCX)

TipRanksJan 7 04:42

Piper Sandler Maintains Neutral on OncoCyte, Lowers Price Target to $3

BenzingaNov 13, 2023 15:18

OncoCyte Analyst Ratings

BenzingaNov 13, 2023 15:18

OncoCyte (OCX) Gets a Hold From Piper Sandler

TipRanksNov 13, 2023 06:19

Needham Maintains Buy on OncoCyte, Lowers Price Target to $3.6

BenzingaNov 9, 2023 10:43

OncoCyte Analyst Ratings

BenzingaNov 9, 2023 10:42

Benchmark Adjusts Price Target on OncoCyte to $5 From $9, Maintains Speculative Buy Rating

MT NewswiresAug 24, 2023 08:25

OncoCyte Analyst Ratings

BenzingaAug 24, 2023 07:59